



Six generic questions that SMC asks in relation to each submission:

Please answer the questions in relation to the licensed indication/positioning:

1. What prescribing guidelines are available, or in preparation, which could influence Scottish prescribing in the indication under review/positioning proposed by the company?
2. Does the medicine under review fill any unmet need (i.e. used in a therapeutic area where there is currently no satisfactory treatment(s)).
3. What are the current treatments used in Scotland for the indication under review (including non-pharmacological options if relevant)? Please indicate which is the predominant treatment and what is your preferred treatment (if different to predominant treatment).
4. If accepted for use, what treatment is most likely to be displaced by the medicine in the indication under review/positioning proposed by the company?
5. SMC has a role to provide advice on the clinical and cost-effectiveness of new medicines compared to existing treatments. If you have knowledge of this particular new product:
 - a) Do you consider it to be a therapeutic advancement in the treatment of the indication under review? If so, please explain
 - b) Describe how it might fit into your treatment plan (e.g. situations where it might be more appropriate).
 - c) Are there any further issues that might be relevant to introduction of this medicine into clinical practice (e.g. service implications).
6. Disease prevalence: if you have this information, please estimate how many patients are likely to be eligible for treatment with the new product in your Health Board or catchment area and/or in Scotland. (Please specify Health Board or catchment area)